Century Therapeutics targets CNTY-813 type 1 diabetes IND filing in Q4 2026

PUBT·06/08/2026 20:06:04

Listen to the news

Century Therapeutics presented new preclinical CNTY-813 data at the ADA 2026 meeting, positioning the program toward a first-in-human study.
Studies showed sustained blood-sugar control with no signs of abnormal cell growth, supporting the therapy’s functional performance and safety profile.
Immune-evasion engineering helped the transplanted cells keep working under immune attack in animal models, pointing to reduced need for immunosuppression.
A Phase 1 manufacturing process was established, a key step for trial supply and potential scale-up.
IND filing remains targeted for 4Q 2026; initial clinical readouts are expected in 2H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606081605PRIMZONEFULLFEED9733527) on June 08, 2026, and is solely responsible for the information contained therein.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number :+852 3852 8500

Monday 7:00 AM - Saturday 9:00 AM (HKT)

Service Email :service@webull.hk

Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)

Business Cooperation :marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English